Introduction
============

Chronic obstructive pulmonary disease (COPD) is characterized by airflow obstruction caused by chronic bronchitis, emphysema, and/or disease of small airways.[@b1-copd-10-145] It is predicted that COPD will be the third leading cause of death worldwide by 2020, and will, thus, impose an even greater burden on health care systems globally.[@b2-copd-10-145] In the People's Republic of China, many people suffer from this disease and a large number die prematurely because of its complications. Therefore, there is an urgent need to prevent and treat this devastating lung disease through better understanding of its pathogenesis. The most important exogenous risk factor for developing COPD is inhalation of tobacco smoke. However, the fact that fewer than 20% of smokers develop COPD[@b3-copd-10-145]--[@b5-copd-10-145] suggests that other factors besides smoking, such as genetic variation, may play a role in the development and severity of COPD.[@b6-copd-10-145]--[@b8-copd-10-145]

Many studies of candidate genes for COPD and pulmonary function have been conducted over the past few years. Of these, genome-wide association (GWA) studies have identified some loci associated with susceptibility to COPD,[@b9-copd-10-145]--[@b11-copd-10-145] but with varying degrees of reproducibility. Conflicting results among these studies may be attributable to differences in ethnicity and sample sizes. Furthermore, few studies performed on the Chinese population have focused on COPD. The previous gene studies of the Chinese population have only focused on the Han population, but Hainan is a multiethnic mix province, while Han and Li are the two main ethnicities, and the incidence of COPD in the Hainan population is higher than that of other regions of China. Therefore, to explore the contribution of genetic factors to the development of COPD in the Chinese population, we performed a case-control study of a Chinese population of Hainan province to identify loci associated with COPD among 14 single-nucleotide polymorphisms (SNPs) of eleven genes.

Materials and methods
=====================

Study participants
------------------

We recruited 200 subjects (58 females, 142 males; median age, 71.70 years) who were diagnosed with COPD at People's Hospital of Hainan Province. COPD was newly diagnosed according to the criteria established by the NHLBI (National Heart, Lung, and Blood Institute)/WHO Global initiative for chronic Obstructive Lung Disease (GOLD).[@b12-copd-10-145] The entry criteria for COPD cases were post-bronchodilator forced expiratory volume in 1 second (FEV1) \<80% predicted and FEV1/forced vital capacity \<0.7. The controls were selected based on post-bronchodilator FEV1 \>80% predicted and FEV1/forced vital capacity \>0.7. The severity of COPD was classified by the guidelines of GOLD in terms of the percentage predicted FEV1: mild (\>80%), moder ate (50%--80%), severe (30%--50%), or very severe (\<30%). Patients were excluded from the study if they had other significant respiratory diseases, such as lung cancer, pulmonary tuberculosis, cystic fibrosis, or bronchial asthma.

Smoking habit was defined as follows: nonsmokers had never smoked; ex-smokers had smoked daily and given it up prior to entering the study; smokers smoked daily at the time of the study.

In addition, 401 randomly selected healthy individuals (115 females, 286 males; median age 48.58 years) were taken as a control group, which included current or ex-smoker with no known disease, no history of any disease, and no airflow limitation. All participants were from Li and Han populations of Hainan province.

Demographic and clinical data
=============================

Demographic and personal data were collected through an in-person interview using a standardized epidemiological questionnaire that included age, sex, ethnicity, residential region, diet, smoking history, and family history of COPD. All of the participants signed informed consent forms at the start of the study. Five milliliters of peripheral blood was taken from each subject according to the study protocol approved by the People's Hospital of Hainan Province.

Tag SNPs selection and genotyping
=================================

GWA studies have identified some loci associated with susceptibility to COPD.[@b10-copd-10-145],[@b13-copd-10-145]--[@b17-copd-10-145] Of these, SNP variants, have been researched in Chinese, however, the results in GWA and Chinese studies were inconsistent across studies. We selected 14 tag SNPs (tSNPs) from eleven genes that were previously reported to be associated with COPD with minor allele frequency \>5% in the HapMap Chinese Han Beijing population. Genomic DNA was extracted from whole blood using the GoldMag-Mini Whole Blood Genomic DNA Purification Kit (GoldMag Co. Ltd., Xi'an City, People's Republic of China). DNA concentration was measured using a NanoDrop 2000 (Thermo scientific, Fitchburg, WI, USA). We used Sequenom MassARRAY Assay Design 3.0 Software (San Diego, California, USA) to design a Multiplexed SNP MassEXTEND assay.[@b18-copd-10-145] The SNPs were genotyped with a Sequenom MassARRAY RS1000 using the standard protocol recommended by the manufacturer.[@b18-copd-10-145] Data management and analysis were performed using Sequenom Typer 4.0 software.[@b18-copd-10-145],[@b19-copd-10-145] Laboratory personnel were blinded to the genotyping results of all samples.

Statistical analysis
====================

Microsoft Excel (Microsoft Corporation, Redmond, WA, USA) and SPSS 19.0 statistical package (IBM Corporation, Armonk, NY, USA) were used to perform statistical analyses. All *P*-values in this study were two-sided and *P*=0.05 was considered the threshold for statistical significance. The genotypic distribution of each SNP in control subjects was tested for departure from Hardy-Weinberg equilibrium (HWE) using an exact test. We compared the allele frequencies of cases and controls using the Pearson's *χ*^2^ and Fisher's exact tests. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated by unconditional logistic regression analysis adjusted for age and sex.[@b20-copd-10-145] The most common genotype in the controls was used as the reference group. Associations between the selected SNPs and the risk of COPD were assessed using genotypic model analysis (codominant, dominant, recessive, over-dominant, and log-additive) by the website software program SNPStats.[@b21-copd-10-145] ORs and 95% CIs were calculated by unconditional logistic regression analysis adjusted for age and sex.[@b20-copd-10-145] Akaike's information criterion and Bayesian information criterion were used to determine the best-fitting model for each SNP. We used the Haploview software package (version 4.2) and SHEsis software platform[@b22-copd-10-145] for analyses of linkage disequilibrium (LD), haplotype construction, and genetic association at polymorphism loci, and a D**′** value \>0.8 indicated that the related tSNPs formed one block.[@b23-copd-10-145],[@b24-copd-10-145]

Results
=======

The distribution of selected characteristics of the cases and controls is shown in [Table 1](#t1-copd-10-145){ref-type="table"}. There were no significant differences in sex, nationality, and smoking status between the two groups (*P*=0.935, 0.889, and 0.889, respectively); however, age was significantly different between COPD patients and healthy controls (*P*\<0.001). Variables of age, sex, nationality, and smoking status were adjusted further for any residual confounding effect in later multivariate logistic regression analyses. Because our sample size was relatively small, we did not conduct population stratification for smoking status.

[Table 2](#t2-copd-10-145){ref-type="table"} shows the minor allele frequency of all SNPs genotyped. The HWE test revealed that the genotypic distribution of rs8102683 and rs7260329 deviated from HWE in the controls of this study (*P*\<0.01). Using the *χ*^2^ test, one SNP (rs10007052 in the *RNF150* gene) was significantly associated with COPD risk at a 5% level (OR =1.43, 95% CI, 1.06--1.95, *P*=0.020). Moreover, rs10007052 remained significantly associated with COPD after further adjustment (*P*=0.021). The other SNPs did not show a significant association with the risk of COPD after adjustment.

We hypothesized that harboring the minor allele of each SNP was a risk factor, compared with possessing the wild-type allele. The results of the various genetic models are displayed in [Tables 3](#t3-copd-10-145){ref-type="table"} and [4](#t4-copd-10-145){ref-type="table"}. Our analyses showed that the genotype "C/A-C/C" of rs10007052 in the *RNF150* gene was associated with an increased risk of COPD in the dominant model before (OR =1.56, 95% CI, 1.08--2.24, *P*=0.018) and after (adjusted OR =1.73, 95% CI, 1.03--2.90, *P*=0.039) adjustment. Similarly, in the log-additive model, rs10007052 also showed significant association with COPD risk before (OR =1.43, 95% CI, 1.05--1.95, *P*=0.022) and after (OR =1.68, 95% CI, 1.06--2.65, *P*=0.026) adjustment ([Table 3](#t3-copd-10-145){ref-type="table"}). However, in the over-dominant model, the C/A genotype of rs10007052 conferred an increased risk before (OR =1.49, 95% CI, 1.03--2.17, *P*=0.037) but not after (OR =1.55, 95% CI, 0.91--2.64, *P*=0.100) adjustment for age, sex, and smoking.

In contrast, the genotype "C/T-C/C" of rs3733829 in the *EGLN2* gene showed a decreased risk in the dominant model before (OR =0.69, 95% CI, 0.49--0.98, *P*=0.041) and after (OR =0.55, 95% CI, 0.33--0.90, *P*=0.018) adjustment for age, sex, and smoking ([Table 4](#t4-copd-10-145){ref-type="table"}). Moreover, in the log-additive model, rs3733829 showed a significant association after further adjustment (OR =0.68, 95% CI, 0.48--0.98, *P*=0.03 \[[Table 4](#t4-copd-10-145){ref-type="table"}\]).

LD and haplotype analyses of the SNPs in the case and control samples were further studied. We ignored pairwise distance among SNPs \>500 kb in the LD analysis. One block each was detected for the studied *EGLN2* SNPs and *HHIP* SNPs by haplotype analyses. The LD for each pair of SNPs is measured by the D**′** value, which is marked in the square. Variants with the red square indicate that the two related sites are in complete LD (D′=1). The two related sites, rs1828591 and rs13118928, were in complete LD (D′=1), while rs1828591 and rs 13141641, as well as rs13141641 and rs13118928, were not in complete (D′=0.95 and 0.96, respectively). The results of the association between the *EGLN2* haplotype and the risk of COPD are listed in [Table 5](#t5-copd-10-145){ref-type="table"}. We found that the CT haplotype was more frequent among patients with COPD and may function as a potential risk factor of COPD after adjustment (adjusted OR =1.55, 95% CI, 1.05--2.31, *P*=0.029). Strong levels of LD between the two SNPs rs1828591 and rs13118928 were observed ([Figure 1](#f1-copd-10-145){ref-type="fig"}).

Discussion
==========

Although a number of COPD risk variants have now been identified, almost all have been through analyses based on European Caucasian populations. Because there are significant differences in the prevalence of COPD and the frequencies of genetic variations among different ethnic populations, it is greatly important to explore the effects of these variations in other populations. We therefore investigated whether the SNP at each locus was associated with COPD in Hainan Chinese population.

In this case-control study, we genotyped 14 tSNPs in the Han and Li Chinese population, and identified one risk SNP in the allelic model and two risk SNPs in the genetic model analysis. Our results suggest that polymorphisms of the corresponding genes may play an important role in the risk of COPD among the Chinese population in Hainan province.

*RNF150* (ring finger protein 150) encodes a RING finger (RNF) protein. An important paralogue of this gene is *ZNRF3*. A large number of RNF proteins are present in eukaryotic cells, and the majority of them are believed to function as E3 ubiquitin ligases.[@b25-copd-10-145] The human genome encodes approximately 300 RNF proteins, many of which are soluble proteins that play a role in a variety of cellular functions, including oncogenesis, development, signal transduction, cell cycle and apoptosis, protein quality control, protein trafficking, cell proliferation and differentiation, apoptosis, immune regulation, signaling, and mitochondrial dynamics.[@b26-copd-10-145],[@b27-copd-10-145] The rs10007052 SNP in *RNF150* did not reach genome-wide statistical significance regarding its relationship to COPD in Europeans in a previously reported GWA study.[@b13-copd-10-145] To our knowledge, the present study is the first report that polymorphisms of *RNF150* affect the pathogenesis of COPD in a Chinese Han and Li population, and these findings provide novel insight into the pathogenesis of COPD. However, the underlying mechanisms of the functional changes induced by mutated *RNF150* are not fully understood and need to be further elucidated; this represents a future direction of study on *RNF150*. Although our present study indicated the novel association between *RNF150* polymorphisms and risk of COPD development, there are some intrinsic limitations. First, the sample size in our study was relatively small. Second, the race of all of the studied participants was Han and Li Chinese. Whether the conclusions of the present study also apply to other races needs to be clarified.

*EGLN2* (Egl nine homolog 2) is one of three similar genes that act in the hypoxia-response pathway and is widely expressed in multiple tissues including brain, lung, and muscle. *EGLN2* regulates the activity of NF-kB, a key transcriptional factor involved in activation of inflammatory and immune genes, including those implicated in COPD pathogenesis.[@b28-copd-10-145],[@b29-copd-10-145] Relevant to the disordered epithelium observed in COPD, *EGLN2* increases cell proliferation through the regulation of cyclin D.[@b30-copd-10-145] It has been reported that increased *EGLN2* expression is associated with impaired epithelial junctional barrier function, which leads to increased epithelial permeability.[@b31-copd-10-145] A recent GWA study found an association of *EGLN2* with COPD risk.[@b13-copd-10-145] The polymorphism, rs3733829, lies in the first intron of the *EGLN2* gene, which is located on chromosome 19q13, 40 kb on the 3′ end of *CYP2A6*. Because of the proximity of *EGLN2* to *CYP2A6*, rs3733829 was assumed to be a proxy for functional genetic variation in *CYP2A6*.[@b15-copd-10-145] *CYP2A6* is an established candidate gene for smoking addiction because it encodes an enzyme involved in the metabolic inactivation of nicotine to cotinine.[@b32-copd-10-145] An association between rs3733829 and *EGLN2* mRNA levels has been demonstrated in monocytes and lymphocytes,[@b32-copd-10-145],[@b34-copd-10-145] and another study reported a potential role in smoking behavior.[@b15-copd-10-145] We found that rs3733829 had a significant effect on COPD risk in the Hainan population; however, because our sample size was relatively small, we did not conduct population stratification of smokers, therefore, we have not confirmed that this locus is significant in smokers. We will increase the sample size in subsequent experiments.

Despite the current study possessing enough power, some limitations should be considered. Firstly, because our sample size was relatively small, we did not conduct population stratification of smokers, therefore, we have not confirmed that this locus is significant in smokers. We will increase the sample size in subsequent experiments. Secondly, the heterogeneity in smoking behaviors and comorbidities was not evaluated in this study, and evaluation of heterogeneity in smoking behaviors has contributed to the progress in elucidating the pathogenesis of COPD in other studies.

Two previous GWA studies showed that two SNPs near the *HHIP* gene (rs13118928 and rs1828591) are associated with COPD and lung function in non-Asian populations.[@b9-copd-10-145],[@b10-copd-10-145] Although our results did not indicate that either rs13118928 or rs1828591 were associated with COPD or lung function in the Chinese Han population, strong levels of LD between rs1828591 and rs13118928 were observed, which was reflected in the very similar ORs obtained in our analysis of the distribution of these two SNPs in COPD patients and controls.

Conclusion
==========

In summary, our present study provides the first demonstration that the rs10007052 SNP of the *RNF150* gene and rs3733829 of the *EGLN2* gene are significantly associated with the risk of COPD in Chinese populations of Hainan province. In addition to the potential role of *EGLN2* genetic polymorphisms in COPD development, our findings suggest that polymorphisms of *RNF150* may be a novel underlying mechanism of COPD pathogenesis.
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###### 

Characteristics of COPD patients and control participants

                            Cases (n=200)   Controls (n=401)   *P*-value from *χ*^2^ test          
  ------------------------- --------------- ------------------ ---------------------------- ------ ---------
  Sex                                                                                              
   Female                   58              29.0               115                          28.7   0.935
   Male                     142             71.0               286                          71.3   
  Age (years)                                                                                      
   Mean                     71.70                              48.58                               \<0.001
  Nationality                                                                                      
   Han Chinese              166             83.0               331                          82.5   0.889
   Li Chinese               34              17.0               70                           17.5   
  Smoking status                                                                                   
   Nonsmoker                103             51.5               210                          52.4   0.889
   Smoker                   97              48.5               191                          47.6   
  Number of smokers                                                                                
   1--10 cigarettes a day   14              7.0                39                           9.7    No data
   20+ cigarettes a day     26              13.0               20                           5.0    
   30+ cigarettes a day     53              26.5               78                           19.5   
  Clinical stages                                                                                  
   Stage I                  80              40.0                                                   
   Stage II                 84              42.0                                                   
   Stage III                26              13.0                                                   
   Stage IV                 10              5.0                                                    

**Abbreviation:** COPD, chronic obstructive pulmonary disease.

###### 

Basic information on candidate tSNPs and their association with COPD risk in this study

  SNP ID       Gene name    Chromosome   Base change   MAF (case)   MAF (control)   *P*-HWE         OR (95% CI)         *P*^a^                                              *P*^b^
  ------------ ------------ ------------ ------------- ------------ --------------- --------------- ------------------- --------------------------------------------------- ---------------------------------------------------
  rs1124480    *WNT7A*      3p25.1       C/T           0.228        0.239           0.782           0.94 (0.71--1.25)   0.667                                               0.665
  rs7671167    *FAM13A*     4q22.1       T/C           0.475        0.481           0.318           0.98 (0.77--1.24)   0.837                                               0.840
  rs10007052   *RNF150*     4q31.21      C/A           0.235        0.176           0.599           1.43 (1.06--1.95)   0.020[\*](#tfn2-copd-10-145){ref-type="table-fn"}   0.021[\*](#tfn2-copd-10-145){ref-type="table-fn"}
  rs1828591    *HHIP*       4q31.21      G/A           0.286        0.298           0.146           0.95 (0.72--1.23)   0.681                                               0.691
  rs13118928   *HHIP*       4q31.21      G/A           0.281        0.288           0.222           0.97 (0.74--1.27)   0.821                                               0.825
  rs13141641   *HHIP*       4q31.21      C/T           0.290        0.287           0.221           1.01 (0.78--1.32)   0.913                                               0.915
  rs13181561   *TMEM173*    5q31.2       A/G           0.327        0.383           0.833           0.78 (0.61--1.01)   0.057                                               0.062
  rs3851050    *PLAC9*      10q22.3      C/T           0.315        0.291           0.276           1.12 (0.87--1.46)   0.382                                               0.373
  rs954820     *JAKMIP3*    10q26.3      G/A           0.255        0.248           1.000           1.04 (0.79--1.37)   0.796                                               0.792
  rs7937       *EGLN2*      19q13.2      C/T           0.413        0.364           0.829           1.23 (0.96--1.57)   0.101                                               0.103
  rs3733829    *EGLN2*      19q13.2      C/T           0.354        0.407           0.680           0.80 (0.62--1.02)   0.077                                               0.078
  rs8102683    *CYP2A6*     19q13.2      T/C           0.237        0.232           0.0000478       1.03 (0.77--1.37)   0.836                                               0.849
  rs7260329    *CYP2B6*     19q13.2      G/A           0.305        0.287           4.397×10^−96^   1.09 (0.84--1.42)   0.513                                               0.642
  rs2823743    *C21orf34*   21q21.1      C/T           0.510        0.476           0.764           1.14 (0.90--1.45)   0.271                                               0.266

**Notes:**

*P*\<0.05 indicates statistical significance. *P*^a^: *P*-values were calculated from chi-square tests or Fisher's exact tests; *P*^b^: *P*-values were calculated from Cochran-armitage trend test

**Abbreviations:** 95% CI, 95% confidence interval; COPD, chronic obstructive pulmonary disease; HWE, Hardy-Weinberg equilibrium; MAF, minor allele frequency; Or, odds ratio; SNP, single-nucleotide polymorphisms; tSNPs, tag SNPs.

###### 

Association between rs10007052 genotypes and COPD risk under different genotypic models

  Model           Genotype      Control       Case          Without adjustment                                  With adjustment                                                         
  --------------- ------------- ------------- ------------- --------------------------------------------------- ------------------- --------------------------------------------------- -------------------
  Codominant      A/A           257 (68.2%)   106 (57.9%)   0.060                                               1.00                0.082                                               1.00
  C/A             107 (28.4%)   68 (37.2%)                  1.54 (1.05--2.25)                                                       1.63 (0.95--2.79)                                   
  C/C             13 (3.5%)     9 (4.9%)                    1.68 (0.70--4.04)                                                       3.16 (0.73--13.66)                                  
  Dominant        A/A           257 (68.2%)   106 (57.9%)   0.018[\*](#tfn4-copd-10-145){ref-type="table-fn"}   1.00                0.039[\*](#tfn4-copd-10-145){ref-type="table-fn"}   1.00
  C/A-C/C         120 (31.8%)   77 (42.1%)                  1.56 (1.08--2.24)                                                       1.73 (1.03--2.90)                                   
  Recessive       A/A-C/A       364 (96.5%)   174 (95.1%)   0.410                                               1.00                0.180                                               1.00
  C/C             13 (3.5%)     9 (4.9%)                    1.45 (0.61--3.45)                                                       2.71 (0.64--11.53)                                  
  Over-dominant   A/A-C/C       270 (71.6%)   115 (62.8%)   0.037[\*](#tfn4-copd-10-145){ref-type="table-fn"}   1.00                0.100                                               1.00
  C/A             107 (28.4%)   68 (37.2%)                  1.49 (1.03--2.17)                                                       1.55 (0.91--2.64)                                   
  Log-additive    --            --            --            0.022[\*](#tfn4-copd-10-145){ref-type="table-fn"}   1.43 (1.05--1.95)   0.026[\*](#tfn4-copd-10-145){ref-type="table-fn"}   1.68 (1.06--2.65)

**Notes:**

*P*\<0.05 indicates statistical significance. *P*^a^: *P*-values were calculated from two-sided chi-square tests or Fisher's exact tests for either genotype distribution. *P*^b^: *P*-values were calculated by unconditional logistic regression adjusted for age, sex, and smoking.

**Abbreviations:** 95% CI, 95% confidence interval; COPD, chronic obstructive pulmonary disease; OR, odds ratio.

###### 

Association between rs3733829 genotypes and COPD risk under different genotypic models

  Model           Genotype      Control       Case          Without adjustment                                  With adjustment                                                         
  --------------- ------------- ------------- ------------- --------------------------------------------------- ------------------- --------------------------------------------------- -------------------
  Codominant      T/T           138 (34.6%)   86 (43.2%)    0.120                                               1.00                0.059                                               1.00
  C/T             197 (49.4%)   85 (42.7%)                  0.69 (0.48--1.00)                                                       0.54 (0.32--0.93)                                   
  C/C             64 (16%)      28 (14.1%)                  0.70 (0.42--1.18)                                                       0.55 (0.26--1.16)                                   
  Dominant        T/T           138 (34.6%)   86 (43.2%)    0.041[\*](#tfn6-copd-10-145){ref-type="table-fn"}   1.00                0.018[\*](#tfn6-copd-10-145){ref-type="table-fn"}   1.00
  C/T-C/C         261 (65.4%)   113 (56.8%)                 0.69 (0.49--0.98)                                                       0.55 (0.33--0.90)                                   
  Recessive       T/T-C/T       335 (84%)     171 (85.9%)   0.530                                               1.00                0.430                                               1.00
  C/C             64 (16%)      28 (14.1%)                  0.86 (0.53--1.39)                                                       0.76 (0.38--1.52)                                   
  Over-dominant   T/T-C/C       202 (50.6%)   114 (57.3%)   0.120                                               1.00                0.077                                               1.00
  C/T             197 (49.4%)   85 (42.7%)                  0.76 (0.54--1.08)                                                       0.64 (0.39--1.05)                                   
  Log-additive    --            --            --            0.077                                               0.80 (0.62--1.03)   0.037[\*](#tfn6-copd-10-145){ref-type="table-fn"}   0.68 (0.48--0.98)

**Notes:**

*P*\<0.05 indicates statistical significance. *P*^a^: *P*-values were calculated from two-sided chi-square tests or Fisher's exact tests for either genotype distribution. *P*^b^: *P*-values were calculated by unconditional logistic regression adjusted for age, sex, and smoking.

**Abbreviations:** 95% CI, 95% confidence interval; COPD, chronic obstructive pulmonary disease; OR, odds ratio.

###### 

*EGLN2* haplotype frequencies and their associations with COPD risk

  Block   Haplotype   Frequency   OR (95% CI)         *P*^a^   Frequency   OR (95% CI)         *P*^b^
  ------- ----------- ----------- ------------------- -------- ----------- ------------------- ---------------------------------------------------
  1       TC          0.3876      1.00                --       0.3883      1.00                --
  2       CT          0.3772      1.31 (1.00--1.73)   0.055    0.3793      1.55 (1.05--2.31)   0.029[\*](#tfn9-copd-10-145){ref-type="table-fn"}
  3       TT          0.2331      1.15 (0.84--1.57)   0.39     0.23        1.30 (0.83--2.05)   0.26

**Notes:** *P*^a^: *P*-values were calculated from two-sided chi-square tests or Fisher's exact tests for either genotype distribution. *P*^b^: *P*-values were calculated by unconditional logistic regression adjusted for age, sex, and smoking.

*P*\<0.05 indicates statistical significance.

**Abbreviations:** 95% CI, 95% confidence interval; COPD, chronic obstructive pulmonary disease; OR, odds ratio.
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